Aktienanalyse zu AIM ImmunoTech Inc (AIM)AIMAIM ImmunoTech Inc

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship product Ampligen is a double-stranded ribonucleic acid (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Alferon N Injection (Interferon alfa) is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. It is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferons. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

AIM ImmunoTech Inc is currently trading at $0.26, which is significantly lower than its 52-week high. The RSI is at 58.91, indicating a neutral momentum. However, the stock has a forward P/E of 2.01, suggesting potential undervaluation. The major risk is the substantial year-to-date decline of 78.26%, indicating ongoing challenges.